Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RIKEN-NKT
- Development stage
- Unknown
- Lead developer
- RIKEN Immune Regenerative Medicine
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Administration
- Intravenous, Subcutaneous
01
Overview
RIKEN-NKT is an autologous NKT cell-targeted immunotherapy developed by RIKEN Immune Regenerative Medicine in collaboration with RIKEN and Chiba University. The therapy utilizes autologous dendritic cells pulsed with alpha-galactosylceramide (α-GalCer) presented on CD1d molecules. Upon intravenous or subcutaneous administration, these antigen-presenting cells selectively activate invariant natural killer T (iNKT) cells in the patient's body. Activated iNKT cells produce large amounts of interferon-gamma (IFN-γ), which subsequently activates both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immune systems to mount a sustained, multi-pronged attack against cancer cells. RIKEN-NKT has been evaluated in Phase 1/2 clinical trials for advanced lung cancer and head and neck cancer, and is offered as a self-pay regenerative medical treatment in Japan.
- Brand names
- RIKEN-NKTRIKEN-NKT IIRIKNKT
- Other names
- Alpha-galactosylceramide-stimulated autologous dendritic cell therapyAutologous NKT cell-activating cell therapyNKT cell-targeted therapy
02
Targets
IFNG (Interferon gamma)iNKT TCR (Invariant natural killer T-cell receptor)CD1D (Tumor-associated macrophage/myeloid-derived suppressor cell CD1d complex)
Beyond the preview
Go deeper on RIKEN-NKT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RIKEN-NKT.